0000899243-17-012356.txt : 20170508 0000899243-17-012356.hdr.sgml : 20170508 20170508203250 ACCESSION NUMBER: 0000899243-17-012356 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170504 FILED AS OF DATE: 20170508 DATE AS OF CHANGE: 20170508 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CZEREPAK ELIZABETH CENTRAL INDEX KEY: 0001263500 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 17824131 MAIL ADDRESS: STREET 1: 201 ROUTE 17 NORTH CITY: RUTHERFORD STATE: NJ ZIP: 07070 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-05-04 0 0001326190 Altimmune, Inc. NASDAQ:ALT 0001263500 CZEREPAK ELIZABETH 19 FIRSTFIELD ROAD, SUITE 200 GAITHERSBURG MD 20878 0 1 0 0 See Remarks Stock Option (option to buy) 13.35 2017-05-04 4 A 0 178595 A 2025-05-27 Common Stock, par value $0.0001 178595 178595 D Stock Option (option to buy) 13.38 2017-05-04 4 A 0 18727 A 2016-04-07 Common Stock, par value $0.0001 18727 18727 D The option is currently exercisable to purchase 119,207 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The option to purchase the remaining 59,388 shares of Common Stock will vest in equal installments on a monthly basis until 4/7/2019. Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. The option is currently exercisable to purchase 6,250 shares of the Issuer's Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020. Chief Financial Officer and Executive Vice President of Corporate Development /s/ Ori Solomon, Attorney in fact for Elizabeth A Czerepak 2017-05-08